Home Companies Catalysts Deep Dives
KRYSTEXXA pegloticase APPROVED
Drug Profile
ModalityPEGylated enzyme
RouteIV
Therapy AreaR&I
Launch2010-09-14
Peak Sales Est$1800M
Formulations[{"id":"krystexxa-iv","doses":"8mg IV infusion every 2 weeks","route":"IV","setting":"INFUSION_CENTE
Companies
AMGN (ORIGINATOR)100%
Mechanism: PEGylated uricase
Expert: PEGylated recombinant uricase (urate oxidase). Converts uric acid to allantoin (5x more soluble). PEGylation extends half-life and reduces immunogenicity. IV Q2W.
Everyday: An enzyme that breaks down uric acid — the crystal-forming substance that causes gout attacks. Normally humans lack this enzyme, so this drug provides it directly, dissolving the uric acid deposits.
Targets: ["URIC ACID"]
Revenue History
PeriodRevenue ($M)
2024$1,185M
2025$1,340M
Programs (2)
IndicationStageKey StudyRegional Status
Chronic refractory goutAPPROVEDMIRROR OL[{"stage":"APPROVED","region":"US","approval_date":"2010-09-14"}]
Uncontrolled goutAPPROVEDMIRROR[{"stage":"APPROVED","region":"US","approval_date":"2010-09-14"}]
Notes
+13% YoY. Acquired via Horizon Therapeutics. Co-administered with methotrexate (MIRROR OL) to reduce immunogenicity and improve response rates.
Data from Supabase · Updated 2026-03-24